
Asaf Maoz/LinkedIn
May 9, 2025, 16:45
Asaf Maoz: Have You Seen Non-Response to Immunotherapy in Locally Advanced dMMR/MSI-H Rectal Cancer?
Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Have you seen non-response to immunotherapy in locally advanced dMMR/MSI-H rectal cancer?
We describe such a case with underlying MMR heterogeneity as a potential mechanism of resistance to dostarlimab.”
Title: Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal Adenocarcinoma
Authors: Asaf Maoz, Ronald Bleday, Jeffrey Goldsmith, Shanna A. Matalon, Mark S. Redston, Molly Nestor, NP, Jonathan A. Nowak, Matthew B. Yurgelun
You can read the Full Article on JCO Precision Oncology.
More posts featuring Dostarlimab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 15:35
May 10, 2025, 15:01
May 10, 2025, 15:01
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57